Net Medical Xpress Solutions (OTCMKTS:NMXS) on April 20, 2022, announced that the firm has been completely accredited by the Better Business Bureau with A+ Rating.
Market Action
On Wednesday, NMXS stock fell 7.22% to $0.0900 with 1.3K share, compared to its average volume of 16K shares. The stock moved within a range of $0.0900 – 0.0970 after opening trade at $0.0970.
Net Medical Accredited With A+ Rating by the Better Business Bureau
CEO Dick Govatski welcomed the A+ Rating from the Better Business Bureau. Govatski added that this is another robust endorsement of the firm’s high operating standards by a widely respected business group. The CEO added that this is especially vital for a firm operating in the medical field.
Better Business Bureau accreditation is given to companies meeting specific standards of integrity and honesty. It gives confidence to customers on dealing with an ethical business.
Established in 1999, Net Medical Xpress has two operating units. The firm gives telemedicine solutions for nursing homes, hospitals, specialty hospitals as well as other medical facilities. Specializing in teleneurosurgery, teleneurology, telecardiology, telewoundcare, teleorthopedics, and telenephrology, the firm maintains a round-the-clock call center.
Additionally, Net Medical Labs is a moderate complex CLIA-certified lab specializing in diagnostics and virus testing. Its mobile fleet of vans is harnessed for giving Flu and Covid testing across companies, schools, homeless shelters as well as nursing homes. The lab is also a reference lab for physician offices as well as other facilities lacking services for complex virus diagnostics.
Key Quote
CEO Dick Govatski said, “We welcome the A+ Rating from the Better Business Bureau. It’s yet another strong endorsement of our company’s high operating standards by a widely respected business group. This is particularly important for a company operating in the medical field.”
Traders Note
NMXS stock is trading below the 20-Day and 50-Day Moving averages of $0.08 and $0.07 respectively. Moreover, the stock is trading is the neutral zone with RSI stands at 53.
 Stock In Focus After Recent Development){kind=link}